BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36093581)

  • 1. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.
    Debernardi S; Blyuss O; Rycyk D; Srivastava K; Jeon CY; Cai H; Cai Q; Shu XO; Crnogorac-Jurcevic T
    Int J Cancer; 2023 Feb; 152(4):769-780. PubMed ID: 36093581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.
    Blyuss O; Zaikin A; Cherepanova V; Munblit D; Kiseleva EM; Prytomanova OM; Duffy SW; Crnogorac-Jurcevic T
    Br J Cancer; 2020 Mar; 122(5):692-696. PubMed ID: 31857725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.
    Radon TP; Massat NJ; Jones R; Alrawashdeh W; Dumartin L; Ennis D; Duffy SW; Kocher HM; Pereira SP; Guarner posthumous L; Murta-Nascimento C; Real FX; Malats N; Neoptolemos J; Costello E; Greenhalf W; Lemoine NR; Crnogorac-Jurcevic T
    Clin Cancer Res; 2015 Aug; 21(15):3512-21. PubMed ID: 26240291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
    Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
    Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
    Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
    Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
    Fahrmann JF; Bantis LE; Capello M; Scelo G; Dennison JB; Patel N; Murage E; Vykoukal J; Kundnani DL; Foretova L; Fabianova E; Holcatova I; Janout V; Feng Z; Yip-Schneider M; Zhang J; Brand R; Taguchi A; Maitra A; Brennan P; Max Schmidt C; Hanash S
    J Natl Cancer Inst; 2019 Apr; 111(4):372-379. PubMed ID: 30137376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
    Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
    BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
    Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
    Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
    Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
    Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
    Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
    Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.